Abstract:The RAS family of GTPases (HRAS, KRAS, NRAS) continue to present formidable challenges to the design of compounds that successfully and specifically target oncogenic RAS mutant populations in cancer. Although recent advances have led to the successful development of inhibitors specific to KRAS G12C (such as Sotorasib [Amgen] and Adagrasib [Mirati Therapeutics]), ongoing efforts seek to develop additional targeted inhibitors for oncogenic mutants of KRAS. Development of new KRAS targeted inhibitors requires the understanding of how a mutation impacts the accessibility of key residues within the protein, along with how each candidate compound interacts with populations of mutant and wild-type proteins. Proteomic analyses, typically comprising peptide-based methods to confirm compound localization or quantify binding kinetics, represent a key validation step for each phase of the inhibitor development process. However, these methods may not always provide a clear picture of how effectively the compound binds to the protein, how specific the compound is to the target residue, and how concentration or incubation time may impact these factors. To address this, we have developed a novel assay to evaluate target engagement in vitro employing top-down proteomics, which entails the analysis of intact protein molecules and their modified forms (proteoforms). By analyzing intact labeled or compound-treated recombinant KRAS4B proteins, we can directly visualize and precisely characterize each species within a sample. This method allows us to easily detect nonspecific binding, identify targeting of incorrect residues, and characterize unanticipated compound reaction products within a short LC-MS run, all facilitated by targeted MS2 fragmentation. Moreover, we have developed complementary methods for RAS proteoform quantitation, allowing for the evaluation of compound engagement to all proteoforms with greater accuracy than traditional peptide-based methods. We first performed a proof-of-concept experiment using a panel of KRAS4B G12D_C118S proteins with selected residues modified to cysteine to evaluate reactivity to maleimide-biotin over time. We then applied our optimized top-down assay to determine the engagement of targeted covalent inhibitors Sotorasib and Adagrasib with KRAS WT, G12C, or G13C in both the active (GppNHp) and inactive (GDPβS) states. Finally, we selected three compounds from a large-scale screen against a UCSF Small Molecule Discovery Center compound library and evaluated each for specificity to KRAS4B G13C over KRAS4B WT and KRAS4B G12C. Our results show the concentration dependence of target engagement and directly map compound binding location(s) without disrupting the protein's primary structure. Moreover, our ability to target discrete compound additions for top-down MS2 fragmentation provides context and order of preferential labeling of KRAS4B. Our hope is that this methodology may help accelerate the identification of new successful targeted inhibitors for KRAS and other RAS isoforms by the greater RAS community. Citation Format: Robert A. D'Ippolito, Caroline J. DeHart, Dana Rabara, Maria Abreu Blanco, Emily Alberico, Nitya Ramakrishnan, Stephanie Widmeyer, Simon Messing, David Turner, Michelle Arkin, Anna Maciag, Andrew Stephen, Dominic Esposito, Frank McCormick, Dwight V. Nissley. A top-down proteomic assay to evaluate KRAS4B-compound engagement [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl) nr A018.

A Suite of Biochemical and Cell-Based Assays for the Characterization of KRAS Inhibitors and Degraders

Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement

Targeting cancer with small-molecule pan-KRAS degraders

Targeting cancer with small molecule pan-KRAS degraders

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Abstract A018: A top-down proteomic assay to evaluate KRAS4B-compound engagement

Biophysical and Biochemical Characterization of Structurally Diverse Small Molecules Hits for KRAS Inhibition

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction

Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Abstract 5328: Novel KRAS-specific in-well lysis ELISA for high throughput screening

Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.

Abstract B040: In silico drug design using KRASG12C as a theranostic target for pancreatic cancer

Design, Synthesis and Biological Evaluation of KRASG12C-PROTACs.

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

Inhibition of prenylated KRAS in a lipid environment

A Pan-Kras Degrader for the Treatment of KRAS-mutant Cancers.

Bioprotacs Establish RAS As a Degradable Target and Provide Novel RAS Biology Insights